TRIMTECH Therapeutics
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
$47MSeed+
Role not disclosedPV
Pfizer Ventures
Activity from announced rounds
Activity in this selectionEurope · Seed
Pfizer Ventures is the venture unit whose official portfolio includes TRIMTECH and TwoStep and whose partner Rana Al-Hallaq is identified in company materials.
Recorded funding activity
TwoStep develops targeted cancer therapies. TRIMTECH develops protein-degrading medicines for neurological disease, while Crossbow develops cancer antibodies. These relationships remain distinct from generic Pfizer corporate participation.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $71.2M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionEnodia Therapeutics
Develops small-molecule therapies for targeted protein degradation at the point of synthesis
€20.7MSeed
Role not disclosed